Janney Capital Maintains Buy On Aegerion Ahead Of 2Q14 Earnings Report
In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals (AEGR) with a $90 price target, which represents a potential upside of 213% from where the stock is currently trading.
Lee noted, “We project Juxtapid sales of $35.8 million and EPS of $(0.42) which is in line with consensus of $35.4 million and $(0.42), respectively. We anticipate management to provide additional clarity on the overall demand in Brazil and commentary on impact of the ongoing investigation in Sao Paulo and the US on sales. In addition, we expect the company to discuss the impact of its recent sales force expansion and realignment on sales and to provide an update on the reimbursement process in EU”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Kimberly Lee currently has a one-year average return of 12.0% and a 53% success rate. Lee has a -17.7% when recommending AEGR, and is ranked #970 out of 3213 analysts.